The Goldman Sachs Group upgraded shares of Hypera (OTCMKTS:HYPMY – Get Rating) from a neutral rating to a buy rating in a research report released on Monday, The Fly reports.
Hypera Trading Up 1.4 %
Hypera stock opened at $9.34 on Monday. The business's 50-day simple moving average is $8.47 and its 200-day simple moving average is $7.98. Hypera has a 52 week low of $4.63 and a 52 week high of $9.37.
Get Hypera alerts:Hypera Company Profile
(Get Rating)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.Featured Articles
- Get a free copy of the StockNews.com research report on Hypera (HYPMY)
- Is it Time to Snack on Mondelez Stock?
- Freeport McMoran Shares Rally Despite Weakening Copper Prices
- Will Matador Share Price Get A Boost From Improved Credit Rating?
- Tesla Stock Slides After Revenue Miss, Musk Maintains Optimism
- AT&T Jumps Higher Thursday After Better-Than-Expected Q3 Results
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.